Table A2.
Hormone Medians and IQRs for Controls by Study
| Hormone Variable | EPIC (n = 26) |
HPFS (n = 22) |
Janus (n = 52) |
Kaiser (n = 73) |
||||
|---|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | Median | IQR | Median | IQR | |
| DHEA, nmol/L | 5.79 | 4.13 to 7.43 | 3.30 | 2.34 to 6.36 | 9.98 | 6.54 to 13.70 | 6.06 | 4.41 to 8.31 |
| Androstenediol, pmol/L | 2,440.17 | 1,865.78 to 2,960.50 | 1,876.82 | 1,188.21 to 2,668.28 | 3,781.97 | 2,780.06 to 5,192.30 | 2,544.48 | 1,934.24 to 3,635.27 |
| Androstenedione, nmol/L | 2.63 | 2.08 to 3.14 | 2.21 | 1.65 to 3.27 | 2.71 | 2.05 to 3.38 | 2.43 | 1.76 to 2.93 |
| Testosterone, nmol/L | 12.70 | 11.25 to 15.94 | 14.00 | 10.71 to 16.86 | 14.51 | 11.39 to 17.92 | 12.04 | 8.35 to 14.59 |
| DHT, pmol/L | 1,602.91 | 1,300.63 to 2,107.15 | 1,281.16 | 1,015.90 to 1,846.84 | 1,494.93 | 1,169.02 to 1,878.91 | 1,292.41 | 1,027.23 to 1,727.27 |
| 3α-diol-3G, nmol/L | 2.95 | 2.24 to 3.82 | 2.50 | 1.72 to 3.54 | 3.87 | 2.74 to 5.55 | 2.70 | 2.09 to 3.88 |
| 3α-diol-17G, nmol/L | 6.24 | 4.42 to 8.89 | 5.24 | 4.11 to 11.16 | 6.89 | 4.44 to 9.44 | 6.88 | 4.96 to 9.24 |
| ADT, pmol/L | 641.06 | 508.92 to 757.44 | 493.78 | 428.11 to 674.84 | 757.82 | 521.93 to 1,077.61 | 695.56 | 532.82 to 951.34 |
| ADT-G, nmol/L | 63.97 | 53.53 to 78.85 | 55.75 | 44.42 to 75.08 | 99.62 | 74.08 to 131.94 | 72.41 | 57.31 to 108.61 |
| Estrone, pmol/L | 80.15 | 69.56 to 118.07 | 91.56 | 85.31 to 98.95 | 67.52 | 56.19 to 86.56 | 75.59 | 59.55 to 94.89 |
| Estradiol, pmol/L | 62.92 | 54.74 to 78.03 | 79.31 | 64.09 to 85.00 | 53.62 | 42.57 to 68.93 | 63.92 | 47.95 to 80.31 |
Abbreviations: 3α-diol-3G, 3-androstanediol-3 glucuronide; 3α-diol-17G, 3-androstanediol-17 glucuronide; ADT, androsterone; ADT-G, androsterone glucuronide; BMI, body mass index; DHEA, dehydroepiandrosterone; DHT, dihydrotestosterone; EPIC, European Prospective Investigation Into Cancer and Nutrition; HPFS, Health Professionals Follow-Up Study; IQR, interquartile range; MEC, Multiethnic Cohort Study of Diet and Cancer; PHS, Physicians' Health Study; PLCO, Prostate, Lung, Colorectal and Ovarian Screening Trial.